Rejtő Judit, Königsbrügge Oliver, Grilz Ella, Hofer Stefanie, Mauracher Lisa-Marie, Gabler Cornelia, Schuster Gerhard, Feistritzer Clemens, Sunder-Plaßmann Raute, Quehenberger Peter, Gebhart Johanna, Ay Cihan, Pabinger Ingrid
Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
IT Systems and Communications, Medical University of Vienna, Vienna, Austria.
J Thromb Haemost. 2020 May;18(5):1081-1086. doi: 10.1111/jth.14770. Epub 2020 Mar 20.
Data on the effect of ABO blood group (ABO), von Willebrand factor (VWF) levels, and age on factor VIII (FVIII) in non-severe haemophilia A (HA) is scarce.
To investigate if ABO, VWF levels, and age have an influence on the variability of FVIII levels and consequently on the assessment of severity in non-severe HA.
PATIENTS/METHODS: Eighty-nine patients with non-severe HA and 82 healthy controls were included. Data on ABO was collected and FVIII clotting activity (FVIII:C) with one-stage clotting assay (FVIII:C OSA) and chromogenic substrate assay (FVIII:C CSA), FVIII antigen (FVIII:Ag) and VWF antigen (VWF:Ag) and activity (VWF:Act) were determined.
In HA, FVIII:C OSA and CSA and FVIII:Ag were not different between non-O (n = 42, median 15.5, interquartile range 10.4-24.0; 10.0, 6.8-26.0 and 15.2, 10.7-24.9) and O (n = 47, 14.1, 9.0-23.0; 10.0, 5.0-23.0 and 15.2, 9.3-35.5), whereas in healthy controls, non-O individuals had significantly higher FVIII levels.
C showed no relevant correlation with VWF levels in HA, but we observed strong correlations in healthy controls. Age had only a minor influence in HA, but had a considerable impact on FVIII:C in healthy controls. In multivariable regression analysis ABO, VWF:Ag and age were not associated with FVIII:C in HA, whereas this model explained 61.3% of the FVIII:C variance in healthy controls.
We conclude that in non-severe HA ABO and VWF levels do not substantially influence the variability of FVIII levels and age has only minor effects on it, which is important information for diagnostic procedures.
关于ABO血型、血管性血友病因子(VWF)水平和年龄对非重度甲型血友病(HA)患者中凝血因子VIII(FVIII)影响的数据较少。
研究ABO血型、VWF水平和年龄是否会影响FVIII水平的变异性,进而影响非重度HA严重程度的评估。
患者/方法:纳入89例非重度HA患者和82例健康对照。收集ABO血型数据,并采用一期凝血试验(FVIII:C OSA)和发色底物法(FVIII:C CSA)测定FVIII凝血活性(FVIII:C)、FVIII抗原(FVIII:Ag)以及VWF抗原(VWF:Ag)和活性(VWF:Act)。
在HA患者中,非O型(n = 42,中位数15.5,四分位数间距10.4 - 24.0;10.0,6.8 - 26.0和15.2,10.7 - 24.9)和O型(n = 47,14.1,9.0 - 23.0;10.0,5.0 - 23.0和15.2,9.3 - 35.5)患者的FVIII:C OSA、FVIII:C CSA和FVIII:Ag无差异,而在健康对照中,非O型个体的FVIII水平显著更高。
在HA患者中,FVIII:C与VWF水平无显著相关性,但在健康对照中观察到强相关性。年龄对HA患者的影响较小,但对健康对照的FVIII:C有显著影响。多变量回归分析显示,ABO血型、VWF:Ag和年龄与HA患者的FVIII:C无关,而该模型可解释健康对照中61.3%的FVIII:C变异。
我们得出结论,在非重度HA中,ABO血型和VWF水平对FVIII水平的变异性影响不大,年龄的影响也较小,这对诊断程序具有重要意义。